VERU Quote, Financials, Valuation and Earnings

Avantor, Inc. has a net margin of -128.15% compared to Veru, Inc.'s net margin of 3.15%. Veru, Inc.'s return on equity of -81.05% beat Avantor, Inc.'s return on equity of -8.99%.

Veru, Inc. has a consensus price target of $25.00, signalling upside risk potential of 941.67%. On the other hand Avantor, Inc. has an analysts' consensus of $10.77 which suggests that it could grow by 36.4%. Given that Veru, Inc. has higher upside potential than Avantor, Inc., analysts believe Veru, Inc. is more attractive than Avantor, Inc..

Veru, Inc. has a beta of -1.351, which suggesting that the stock is 235.097% less volatile than S&P 500. In comparison Avantor, Inc. has a beta of 0.999, suggesting its less volatile than the S&P 500 by 0.113%.

Veru, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 110.4%. Avantor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veru, Inc. pays -- of its earnings as a dividend. Avantor, Inc. pays out -- of its earnings as a dividend.

Veru, Inc. quarterly revenues are --, which are smaller than Avantor, Inc. quarterly revenues of $1.7B. Veru, Inc.'s net income of -$5.3M is lower than Avantor, Inc.'s net income of $52.4M. Notably, Veru, Inc.'s price-to-earnings ratio is -- while Avantor, Inc.'s PE ratio is 10.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veru, Inc. is 38.01x versus 0.84x for Avantor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Humana, Inc. has a net margin of -128.15% compared to Veru, Inc.'s net margin of -2.39%. Veru, Inc.'s return on equity of -81.05% beat Humana, Inc.'s return on equity of 6.77%.

Veru, Inc. has a consensus price target of $25.00, signalling upside risk potential of 941.67%. On the other hand Humana, Inc. has an analysts' consensus of $212.17 which suggests that it could grow by 16.16%. Given that Veru, Inc. has higher upside potential than Humana, Inc., analysts believe Veru, Inc. is more attractive than Humana, Inc..

Veru, Inc. has a beta of -1.351, which suggesting that the stock is 235.097% less volatile than S&P 500. In comparison Humana, Inc. has a beta of 0.439, suggesting its less volatile than the S&P 500 by 56.107%.

Veru, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 110.4%. Humana, Inc. offers a yield of 1.89% to investors and pays a quarterly dividend of $0.89 per share. Veru, Inc. pays -- of its earnings as a dividend. Humana, Inc. pays out 36% of its earnings as a dividend. Humana, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Veru, Inc. quarterly revenues are --, which are smaller than Humana, Inc. quarterly revenues of $32.5B. Veru, Inc.'s net income of -$5.3M is higher than Humana, Inc.'s net income of -$776M. Notably, Veru, Inc.'s price-to-earnings ratio is -- while Humana, Inc.'s PE ratio is 19.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veru, Inc. is 38.01x versus 0.17x for Humana, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Royalty Pharma Plc has a net margin of -128.15% compared to Veru, Inc.'s net margin of 57.24%. Veru, Inc.'s return on equity of -81.05% beat Royalty Pharma Plc's return on equity of 13.52%.

Veru, Inc. has a consensus price target of $25.00, signalling upside risk potential of 941.67%. On the other hand Royalty Pharma Plc has an analysts' consensus of $51.56 which suggests that it could grow by 8.95%. Given that Veru, Inc. has higher upside potential than Royalty Pharma Plc, analysts believe Veru, Inc. is more attractive than Royalty Pharma Plc.

Veru, Inc. has a beta of -1.351, which suggesting that the stock is 235.097% less volatile than S&P 500. In comparison Royalty Pharma Plc has a beta of 0.395, suggesting its less volatile than the S&P 500 by 60.476%.

Veru, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 110.4%. Royalty Pharma Plc offers a yield of 1.94% to investors and pays a quarterly dividend of $0.24 per share. Veru, Inc. pays -- of its earnings as a dividend. Royalty Pharma Plc pays out 49.4% of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Veru, Inc. quarterly revenues are --, which are smaller than Royalty Pharma Plc quarterly revenues of $622M. Veru, Inc.'s net income of -$5.3M is lower than Royalty Pharma Plc's net income of $356M. Notably, Veru, Inc.'s price-to-earnings ratio is -- while Royalty Pharma Plc's PE ratio is 25.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veru, Inc. is 38.01x versus 10.31x for Royalty Pharma Plc. Usually stocks with elevated PS ratios are considered overvalued.

Tenet Healthcare Corp. has a net margin of -128.15% compared to Veru, Inc.'s net margin of 11.65%. Veru, Inc.'s return on equity of -81.05% beat Tenet Healthcare Corp.'s return on equity of 27.41%.

Veru, Inc. has a consensus price target of $25.00, signalling upside risk potential of 941.67%. On the other hand Tenet Healthcare Corp. has an analysts' consensus of $261.38 which suggests that it could grow by 37.37%. Given that Veru, Inc. has higher upside potential than Tenet Healthcare Corp., analysts believe Veru, Inc. is more attractive than Tenet Healthcare Corp..

Veru, Inc. has a beta of -1.351, which suggesting that the stock is 235.097% less volatile than S&P 500. In comparison Tenet Healthcare Corp. has a beta of 1.495, suggesting its more volatile than the S&P 500 by 49.469%.

Veru, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 110.4%. Tenet Healthcare Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veru, Inc. pays -- of its earnings as a dividend. Tenet Healthcare Corp. pays out -- of its earnings as a dividend.

Veru, Inc. quarterly revenues are --, which are smaller than Tenet Healthcare Corp. quarterly revenues of $5.5B. Veru, Inc.'s net income of -$5.3M is lower than Tenet Healthcare Corp.'s net income of $644M. Notably, Veru, Inc.'s price-to-earnings ratio is -- while Tenet Healthcare Corp.'s PE ratio is 12.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veru, Inc. is 38.01x versus 0.82x for Tenet Healthcare Corp.. Usually stocks with elevated PS ratios are considered overvalued.